Docket No.: EBAUL,001APC

Customer No. 20,995

## INFORMATION DISCLOSURE STATEMENT

**Applicant** 

Baulieu et al.

App. No

10/587765

Filed

June 11, 2007

For

TREATMENT OF PULMONARY

ARTERY HYPERTENSION WITH DHEA, DHEAS, DHEA ANALOGS,

OR DHEA DERIVATIVES

Examiner

Unassigned

Art Unit

1617

CERTIFICATE OF EFS WEB TRANSMISSION

I hereby certify that this correspondence, and any other attachment noted on the automated Acknowledgement Receipt, is being transmitted from within the Pacific Time zone to the Commissioner for Patents via the EFS Web

server on:

HARX -+

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 16 references to be considered by the Examiner. Also enclosed are 9 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dotad.

Bv:

Neil 8. Bartfeld, Ph.D.

Registration No. 39901

Agent of Record

Customer No. 20,995

(619) 235-8550